Advertisement
Singapore markets closed
  • Straits Times Index

    3,224.01
    -27.70 (-0.85%)
     
  • Nikkei

    40,168.07
    -594.66 (-1.46%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Bitcoin USD

    70,884.23
    +2,187.20 (+3.18%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.29
    +5.80 (+0.11%)
     
  • Dow

    39,806.85
    +46.77 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Gold

    2,240.80
    +28.10 (+1.27%)
     
  • Crude Oil

    82.97
    +1.62 (+1.99%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • FTSE Bursa Malaysia

    1,530.60
    -7.82 (-0.51%)
     
  • Jakarta Composite Index

    7,288.81
    -21.28 (-0.29%)
     
  • PSE Index

    6,903.53
    +5.36 (+0.08%)
     

Britain expects verdict on Pfizer's COVID-19 vaccine before AstraZeneca's - Times

FILE PHOTO: A woman walks past a sign outside Pfizer Headquarters in the Manhattan borough of New York City

(Reuters) - Senior sources in the British government expect that a verdict on whether Pfizer Inc-backed <PFE.N> COVID-19 vaccine works will be available before the results are in on AstraZeneca Plc's <AZN.L> competing vaccine, the Times reported.

Britain believes that the vaccine, which Pfizer is co-developing with Germany's BioNTech SE <22UAy.F>, could be ready to distribute before Christmas, the report said.

Pfizer's Chief Executive Albert Bourla has previously said the company could release data on whether or not the vaccine works as early as this month.

The U.S. drugmaker said this week if trials are successful the company expects to file for emergency authorization of the vaccine candidate from U.S. regulators shortly after it has enough safety data in late November.

Britain has agreed supply deals for six vaccine candidates including frontrunners from Pfizer and AstraZeneca.

(Reporting by Shubham Kalia in Bengaluru; Editing by Tom Hogue)